Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Nov;64(4):e317-e326.
doi: 10.1111/ajd.14130. Epub 2023 Jul 12.

Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

A Sahuquillo-Torralba  1 , M Hospital-Gil  2 , E Vilarrasa-Rull  3 , M Llamas-Velasco  4 , R Rivera  5 , J M Carrascosa  6 , P de la Cueva-Dovao  7 , S Armesto-Santos  8 , R Ruíz-Villaverde  9 , M Velasco-Pastor  10 , J Magdaleno-Tapial  11 , J I Yanguas-Bayona  12 , M Ribera-Pibernat  13 , L Salgado-Boquete  14 , P Herranz-Pinto  15 , A Romero-Mate  16 , E Martínez-Lorenzo  17 , J L López-Estebaranz  18 , F Ballescá-López  19 , R Botella-Estrada  1   20
Affiliations
Multicenter Study

Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

A Sahuquillo-Torralba et al. Australas J Dermatol. 2023 Nov.

Abstract

Background and objective: The data in clinical practice regarding the effectiveness and safety of brodalumab in psoriasis are scarce, especially at scalp and palmoplantar locations. The main objective was the percentage of patients achieving absolute PASI ≤3/ ≤1/ =0 for plaque psoriasis and the percentage of patients achieving an IGA 0-1/IGA 0 for the special locations at Week 52 of treatment.

Patients and methods: Observational retrospective multicentre study in 28 Spanish Hospitals that included adult patients with plaque psoriasis treated with brodalumab, from September 2018 until March 2021.

Results: A total of 200 patients were included. The mean baseline PASI was 10.97 (±6.28) with a mean basal scalp (n = 58) and palmoplantar (n = 40) IGA of 2.10 (±0.97) and 2.15 (±1.26), respectively. At Week 52, 93.98%/75.90%/68.67% of patients reached an absolute PASI ≤3/ ≤1/ =0 in plaque psoriasis (n = 83), with a percentage of patients achieving scalp (n = 27) and palmoplantar (n = 19) IGA 0-1/IGA 0 of 96.3%/88.9% and 100%/88.9%, respectively. Fifteen per cent of patients reported any adverse events with candidiasis being the most reported (6%), but only 6% of the adverse events required the withdrawal.

Conclusions: Brodalumab demonstrated high PASI and IGA responses and was well tolerated in clinical practice in plaque, scalp and palmoplantar psoriasis.

Keywords: brodalumab; palmoplantar psoriasis; plaque psoriasis; real-world evidence; scalp psoriasis.

PubMed Disclaimer

References

REFERENCES

    1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60:218-224. https://doi.org/10.1016/j.jaad.2008.09.022
    1. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60:394-401. https://doi.org/10.1016/j.jaad.2008.10.062
    1. Ferrándiz C, Bordas X, García-Patos V, Puig S, Pujol R, Smandía A. Prevalence of psoriasis in Spain (Epiderma project: phase I). J Eur Acad Dermatol Venereol. 2001;15:20-23. https://doi.org/10.1046/j.1468-3083.2001.00191.x
    1. Oulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570. https://doi.org/10.7573/dic.212570
    1. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis. N Engl J Med. 2015;373:1318-1328. https://doi.org/10.1056/NEJMoa1503824

Publication types

LinkOut - more resources